Clinical Trial Update: Paclitaxel i.v. Plus Cisplatin i.p for NACT in Patients With Advanced Ovarian Cancer [Phase 3]

View source ↗

Summary

A phase 3 trial evaluating paclitaxel intravenous plus cisplatin intraperitoneal for neoadjuvant chemotherapy in advanced ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Epithelial Cancer

Drugs mentioned

• Cisplatin (i.p.) (cisplatin)
• Paclitaxel (i.v.) (paclitaxel)

Snippet

Sponsor: West China Second University Hospital | Conditions: Epithelial Carcinoma, Ovarian, Neoadjuvant Chemotherapy | Phase 3 | Status: UNKNOWN